Reports Highlight Strengthening Primary Care After the Pandemic

Revakinagene taroretcel-lwey (Encelto; Neurotech), an allogeneic encapsulated cell-based gene therapy, is the first therapy to be approved for macular telangiectasia type 2.

On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.

Nick Webb tells attendees at the Association of Cancer Care Centers that consumer experience and workforce happiness will be keys to success in the future for health systems.

On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.

More than 5 years after the American Society of Clinical Oncology warned of emerging disparities in precision medicine, efforts by community practices to embrace technology, form partnerships, and use data show how patients can gain access to personalized approaches. But challenges remain, especially for those covered by Medicaid.

Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1.